September 26, 2026

Avacincaptad Pegol and Anti-VEGF in Real-World Practice

An IRIS Registry analysis of more than 13,000 eyes found that concomitant anti-VEGF use for nAMD or CNV did not substantially alter complement inhibitor treatment.

September 25, 2026

Tracking Fluid Resolution After Photodynamic Therapy

A single-patient analysis found that more than half of estimated subretinal fluid volume resolved within 9 days of half-fluence PDT for chronic CSCR.

September 25, 2026

Epiretinal Membrane Removal May Reduce Injection Burden in nAMD

In a small retrospective study, two-thirds of patients stopped or reduced anti-VEGF injections following surgery.

September 25, 2026

Study Supports 30-Second Chlorhexidine Protocol for IVI

Aqueous chlorhexidine 0.05% significantly reduced conjunctival bacteria within 30 seconds, supporting a shorter antisepsis protocol using a less irritating alternative to povidone-iodine.

September 25, 2026

A First Look at the LUGANO Data

Charles C. Wykoff, MD, PhD, and Carl Regillo, MD, FACS, examine phase 3 EYP-1901 findings presented for the first time at Retina Society 2026.

September 25, 2026

New Data on Laru-Zova in XLRP

Phase 2 DAWN results provide additional evidence on safety and visual function as the laru-zova program advances through the pivotal VISTA trial.

September 25, 2026

Four-Year Data Show Durable MCO-010 Effect

Long-term follow-up of RESTORE participants shows sustained visual acuity improvements after a single intravitreal administration of the optogenetic therapy.